In What Sense is Digital Nature 'Nature'?The impact of 'nature with mass' accelerates the changes in 'nature without ...
In a Nov. 1 blog post, software engineer Nicolas Chagnet argues that Gleam pairs a simple functional syntax with the Erlang ...
Miner, an efficient spatial data mining framework that discovers dynamic co-location patterns across evolving urban ...
The AI-driven biotech has secured FDA alignment on a pivotal trial for its FAP therapy, with a study start planned for 2027.
Recursion Pharmaceuticals (NASDAQ:RXRX) has aligned with the U.S. Food and Drug Administration on the primary endpoint for a planned Phase III study of its experimental treatment for familial ...
On Nov. 18, 2026, Recursion shares climbed after regulators aligned on its lead familial adenomatous polyposis trial, though ...
REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy ...
Recursion Pharmaceuticals, Inc. ( RXRX) announced Wednesday that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the design of its registrational Phase 3 trial of REC-4881 ...
Recursion Pharmaceuticals said on November 18, 2026 that it had aligned with the U.S. Food and Drug Administration on a ...
Recursion announces FDA alignment for REC-4881’s Phase 3 trial in familial adenomatous polyposis, targeting crucial adenoma excision outcomes.
A Beginner's Guide to the Sliding Window Algorithm with JavaScript Learn the basics of the Sliding Window algorithm in ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...